Previous 10 | Next 10 |
2023-08-08 13:05:05 ET Summary Eli Lilly and Company's Q2 2023 earnings were boosted by strong sales growth of three key products in its pipeline: Verzenio, Jardiance, and Mounjaro. Verzenio, a breast cancer drug, saw significant sales growth due to its approval for multiple indic...
2023-08-08 12:10:35 ET Summary Nektar Therapeutics' lead compound rezpegaldesleukin shows more promising results after errors in efficacy calculations were discovered. Nektar shares surged over 90% following the news, with plans to initiate a Phase IIb study in atopic dermatitis. ...
2023-08-08 06:27:00 ET Is Short or Long Term Investing in Penny Stocks Better? Penny stocks represent a unique opportunity for both seasoned and novice investors to diversify their portfolio and potentially reap significant returns. Characterized by their low stock price, often under $5...
2023-08-07 17:35:20 ET Nektar Therapeutics ( NASDAQ: NKTR ) is scheduled to announce Q2 earnings results on Tuesday, August 8th, after market close. The consensus EPS Estimate is -$0.22 and the consensus Revenue Estimate is $21.83M (+1.1% Y/Y). For further details se...
2023-08-07 13:29:20 ET Nektar ( NASDAQ: NKTR ) is reportedly suing former partner Eli Lilly ( NYSE: LLY ) for allegedly miscalculating key clinical trial data for Nektar's dermatology and immunology drug candidate Rezpeg. Nektar filed suit against Lilly in a federal cour...
2023-08-07 13:28:03 ET Gainers: Nektar Therapeutics ( NKTR ) +87% . Enveric Biosciences ( ENVB ) +47% . Sequans Communications S.A. ( SQNS ) +31% . Tabula Rasa HealthCare ( TRHC ) +31% . Missfresh Limited ( MF ) +29% . Sovos ...
Nektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company Nektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previousl...
Nektar to Announce Financial Results for the Second Quarter 2023 on Tuesday, August 8, 2023, After Close of U.S.-Based Financial Markets PR Newswire SAN FRANCISCO , Aug. 1, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial result...
Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference PR Newswire SAN FRANCISCO , June 12, 2023 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) senior management is scheduled to participate in a virt...
2023-05-24 13:57:04 ET The Russell 3000 index will have a new look on June 26, after the market opens, when 286 securities will be added and 179 securities will be deleted as part of the annual reconstitution. Following are some notable healthcare companies which will be added an...
News, Short Squeeze, Breakout and More Instantly...
Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024 PR Newswire – NKTR-0165 Demonstrates Selective Enhancement of Treg Cell Function Through Novel Agonistic ...
Nektar Management to Present at Upcoming Investor Conferences PR Newswire SAN FRANCISCO , May 30, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at upcoming investor conferences: Jefferies Healthcare C...
Nektar Therapeutics Reports First Quarter 2024 Financial Results PR Newswire SAN FRANCISCO , May 9, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2024 . Cash and ...